Member Info for B_Positive

Roche and NHS not just following GDR, but actively reacting to todays news is a big sign not to be ignored.

Remember there's the cardovasciular angle now too. Not just stroke.

Huge tech

Very interesting seeing the Roche and NHS sales people following GDR.

Were they waiting on this certification before signing up?

I guess we'll find out over the days and weeks ahead.

Given the cost saving and life saving ability of the test, I don't see why someone doesn't cut a huge deal here.

If Roche, then my good, my 10p for 2025 predicition will look like a massive deramp.

Very interesting.

Imagine a deal with Roche.

From here it would be an instant 10-20 bags within a week.

Could they be playing a part in the FDA process, US expansion and UAE expansion?

More news next week and it will be big is my feeling

Https://www.azonano.com/suppliers.aspx?SupplierID=347

The market cap is far far far too low for a company supplying Sony's next generation of products.

Will see an RNS next week I bet.

Waiting for the new website was definitely a key thing for the company.

Now we have confirmation of Sony

I fancy this to beat last years high of 0.50p very soon.

Finish to 0.2p today or above why not.

Criminally undervalued with Sony involved and probably the headphone company.

GDR Market cap: £8M

AGL Market cap: £32M

AVCT Market cap: £100M.

What do they have in common? None are profitable yet.

How does GDR standout? Gendrive has by far the lowest market cap out of the 3, it has the lowest costs and losses and also has many near term catalysts for growth.

Therefore my deduction is that GDR has the highest upside out of the three with the right news.

So much coming

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+UAE Expansion as per LinkedIn

+National rollout in UK for Stroke testing

+National rollout in the UK for cardiovascular testing

+New contracts

+Grants

+Other wildcards

Over £3.0M in the coffers + additional revenues and grant cash = fully funded for 2025.

Now revenues growing on top.

Great stuff overall.

Last year 3 bags after the raise. I fancy 15-20 bags this time considering the magnitude of expansion coming here from both domestic and overseas.

Endorsement is huge.

Implementing the Genedrive® CYP2C19 ID Kit to guide therapy could prevent recurrent strokes and reduce healthcare costs.

Our rapid pharmacogenetic test could prevent more strokes than a centralised laboratory testing model.

NHS Hospital Episode Statistics (HES) data suggests that in England alone, implementing our test could release 62,000 hospital bed days.

https://www.linkedin.com/posts/genedrive-plc_strokeawarenessmonth-precisionmedicine-strokeprevention-activity-7332680664527290368-fCHx/?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

Learn more on our website: https://lnkd.in/eEu59s3t

hashtag#StrokeAwarenessMonth hashtag#PrecisionMedicine hashtag#StrokePrevention hashtag#Pharmacogenomics hashtag#PublicHealth hashtag#GDR

Fancy this to run to 0.5p again this June.

It did so last year.

Then 1.00p+ by year end.

Typo, meant end of June :D

I said from mid-may until end of June.

There is something going on with it in June, as per the patent update in Spring.

June next week so roll on SMT

Riversgold up 25% overnight....

Something is coming.

Bring on next week :D

June feels like SMT update time.

Also further new deals such as the headphone one to come no doubt.

Forgot national NHS expansion too

GDR Market cap: £8M

AGL Market cap: £32M

AVCT Market cap: £100M.

What do they have in common? None are profitable yet.

How does GDR standout? Gendrive has by far the lowest market cap out of the 3, it has the lowest costs and losses and also has many near term catalysts for growth.

Therefore my deduction is that GDR has the highest upside out of the three with the right news.

So much coming

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+UAE Expansion as per LinkedIn

+National rollout in UK for Stroke testing

+National rollout in the UK for cardiovascular testing

+New contracts

+Grants

+Other wildcards

Over £3.0M in the coffers + additional revenues and grant cash = fully funded for 2025.

Now revenues growing on top.

Great stuff overall.

Last year 3 bags after the raise. I fancy 15-20 bags this time considering the magnitude of expansion coming here from both domestic and overseas.

Endorsement is huge.

Implementing the Genedrive® CYP2C19 ID Kit to guide therapy could prevent recurrent strokes and reduce healthcare costs.

Our rapid pharmacogenetic test could prevent more strokes than a centralised laboratory testing model.

NHS Hospital Episode Statistics (HES) data suggests that in England alone, implementing our test could release 62,000 hospital bed days.

https://www.linkedin.com/posts/genedrive-plc_strokeawarenessmonth-precisionmedicine-strokeprevention-activity-7332680664527290368-fCHx/?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

Learn more on our website: https://lnkd.in/eEu59s3t

hashtag#StrokeAwarenessMonth hashtag#PrecisionMedicine hashtag#StrokePrevention hashtag#Pharmacogenomics hashtag#PublicHealth hashtag#GDR

Middle East, Europe and US news to follow.

Along with FDA.

Also further NHS rollout.

Massive massive moment and news for the company

GDR Market cap: £8M

AGL Market cap: £32M

AVCT Market cap: £100M.

What do they have in common? None are profitable yet.

How does GDR standout? Gendrive has by far the lowest market cap out of the 3, it has the lowest costs and losses and also has many near term catalysts for growth.

Therefore my deduction is that GDR has the highest upside out of the three with the right news.

So much coming

+CE MARK

+FDA APPROVAL

+UK Expansion

+Europe Expansion

+US Expansion

+UAE Expansion as per LinkedIn

+National rollout in UK for Stroke testing

+National rollout in the UK for cardiovascular testing

+New contracts

+Grants

+Other wildcards

Over £3.0M in the coffers + additional revenues and grant cash = fully funded for 2025.

Now revenues growing on top.

Great stuff overall.

Last year 3 bags after the raise. I fancy 15-20 bags this time considering the magnitude of expansion coming here from both domestic and overseas.

Endorsement is huge.

Implementing the Genedrive® CYP2C19 ID Kit to guide therapy could prevent recurrent strokes and reduce healthcare costs.

Our rapid pharmacogenetic test could prevent more strokes than a centralised laboratory testing model.

NHS Hospital Episode Statistics (HES) data suggests that in England alone, implementing our test could release 62,000 hospital bed days.

https://www.linkedin.com/posts/genedrive-plc_strokeawarenessmonth-precisionmedicine-strokeprevention-activity-7332680664527290368-fCHx/?utm_source=share&utm_medium=member_ios&rcm=ACoAAALv5fQBpxprk34Npz7-vf2JnQIqouDOeKY

Learn more on our website: https://lnkd.in/eEu59s3t

hashtag#StrokeAwarenessMonth hashtag#PrecisionMedicine hashtag#StrokePrevention hashtag#Pharmacogenomics hashtag#PublicHealth hashtag#GDR